Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepalatide + PEG-IFN in Chronic Hepatitis B
NCT04426968Phase 2Completed
- Sponsor
- Shanghai Hepu Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Nov 2023
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hepalatide in Chronic Hepatitis B (CHB) (4 arms), sponsored by Shanghai Hepu Pharmaceutical. Primary endpoint: Virological response at 24 weeks. Started Jun 2021; status: completed.
02
Drugs
hepalatide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04426968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04426968.